Paxlovid Misses in Standard-Risk COVID-19

(MedPage Today) -- Updated findings from a nirmatrelvir/ritonavir (Paxlovid) trial in standard-risk COVID-19 suggest the antiviral's benefits are less clear for those not at high risk of severe outcomes. As was previously reported, Pfizer's so...
Source: MedPage Today Public Health - Category: American Health Source Type: news